Amgen Inc. (AMGN)
Last closing price (Mar 10 4:00 EDT):
125.40 (2.57%) ?
Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Its principal products include Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body fight infections; Enbrel, an inhibitor of tumor necrosis factor that plays a role in the bodys response to inflammatory diseases; Aranesp and EPOGEN erythropoiesis-stimulating agents that stimulate the production of red blood cells; and XGEVA/Prolia (denosumab) to treat men with castration-resistant prostate cancer at high risk of developing bone metastases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides product candidates in mid- to late-stage development in various therapeutic areas comprising oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine, which includes neuroscience. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc; Takeda Pharmaceutical Company Limited; and UCB. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
|John Eade||Argus Research Company||Buy||Jan 31, '14||118.35||135.00||Jan 31, '15||5.96%|
|Yaron Werber||Citi||Buy||Dec 06, '13||113.54||Dec 06, '14||10.45%|
|M Ian Somaiya||Piper Jaffray||Buy||Nov 26, '13||113.09||Nov 26, '14||10.89%|
|Joshua Schimmer||Lazard Capital Markets||Buy||Nov 26, '13||113.09||Nov 26, '14||10.89%|
|Matt Roden||UBS||Buy||Oct 23, '13||114.61||129.00||Oct 23, '14||9.41%|
|Robyn Karnauskas||Deutsche Bank Securities||Buy||Oct 22, '13||115.14||Oct 22, '14||8.91%|
|Yaron Werber||Citi||Buy||Aug 27, '13||108.13||Aug 27, '14||15.97%|
|Robyn Karnauskas||Deutsche Bank Securities||Buy||Aug 26, '13||112.70||Aug 26, '14||11.27%|
|Ian Somaiya||Piper Jaffray||Buy||Aug 26, '13||112.70||Aug 26, '14||11.27%|
|Michael Yee||RBC Capital Markets||Buy||Aug 01, '13||107.91||125.00||Aug 01, '14||16.21%|
|Tyler Leggett||Unaffiliated||Buy||Jul 24, '13||105.69||117.00||Jan 24, '14||16.95%|
|Robyn Karnauskas||Deutsche Bank Securities||Buy||Jun 12, '13||95.07||Jun 12, '14||31.90%|
|Michael Yee||RBC Capital Markets||Buy||Jun 12, '13||95.07||Jun 12, '14||31.90%|
|Eun Yang||Jefferies & Co.||Buy||Jun 03, '13||97.79||Jun 03, '14||28.23%|
|Gene Mack||Brean Murray, Carret & Co.||Buy||Jun 02, '13||97.79||110.00||Jun 02, '14||28.23%|
|Terence Flynn||Goldman Sachs||Buy||May 22, '13||103.12||May 22, '14||21.61%|
|Robyn Karnauskas||Deutsche Bank Securities||Buy||Apr 23, '13||110.75||115.00||Apr 23, '14||13.23%|
|Joshua Schimmer||Lazard Capital Markets||Buy||Apr 10, '13||106.32||125.00||Apr 10, '14||17.95%|
|Matt Roden||UBS||Buy||Feb 25, '13||87.95||Feb 25, '14||43.02%|
|Joshua Schimmer||Lazard Capital Markets||Buy||Feb 25, '13||87.95||Feb 25, '14||43.02%|